Pharma Consultant Breakfast Session During AAPS

Join this Pharmaceutical consulting event during AAPS PharmSci 360. Hear from experienced industry colleagues on the latest tips that will help your clients avoid critical pitfalls in early development of their drugs to best leverage CDMO experts to help manage and mitigate risks for your clients’ programs. Learn best in class practices from early drug development experts. Get insider info on how to access top experts and capabilities from the leading development and delivery technology partner that progresses hundreds of molecules thru development and launch every year.

This event is designed to promote networking and you will have a chance to discuss your challenges with experts in Catalent’s Science and Technology team. All this and a delicious complimentary breakfast at the Henley Park Hotel just minutes away from the convention center.

November 6, 2018 Henley Park Hotel - Parlor Room in Restaurant
926 Massachusetts Ave NW, Washington, D.C
7:45-9:45 a.m. EST

Featured Keynote Presenter:
Alan F. Parr, Pharm.D., Ph.D. BioCeutics, LLC

The Cost of Failure: How to avoid the critical pitfalls in pharma consulting, and set your clients up for success

We as pharmaceutical consultants find that all our clients have the same goal-- the development of an asset that brings value. Some clients will focus on the value the asset will bring to the intended patient population; others will focus on the increase to the monetary value of the asset. Determining a client’s primary goal is critical to guiding them through the development of their asset. Additionally, their primary focus will impact the strategy used to develop the asset. This presentation will also discuss approaches we can take to ensure the best success for our clients.

Dr. Alan Parr , Pharm.D., Ph.D has worked in the field of Pharmaceutical Sciences for 33 years. His roles in big pharma included formulation scientist, formulation manager, and Director of Biopharmaceutics and responsibilities ranged from development of formulations from the early development phase all the way through to the scale up of commercial size batches. Since June of 2015 Dr. Parr has served as consultant to numerous small pharmaceutical companies. Dr. Parr earned his Pharm.D. degree from the University of Nebraska College of Pharmacy and his Ph.D. from the University of Kentucky College of Pharmacy.

Intro Presenter:
Stephen Tindal, Director of Science & Technology, Catalent

Perspectives in Partnership: How to leverage CDMO expert capabilities to give your clients an edge.

Catalent has a reputation for being a strong partner for the commercial manufacture of oral drug products. Through strategic acquisitions, Catalent has increased emphasis on early drug product development to help de-risk programs prior to phase 1, and to work with entrepreneurial companies to translate discoveries into better treatments for patients. This presentation will review Catalent’s approach to early development: a science and a data-driven approach to select the right molecule, the right form, and the right formulation technology. The presentation will also introduce you to the role of the Science and Technology team and how engagement can increase value you bring to your client by connecting to Catalent’s global expertise.

Stephen Tindal has worked at Catalent for 30 years, holding positions in R&D responsible for Formulation, Process Development and also for clinical and commercial Operations. Stephen specializes in solving complex data analysis challenges such as low bioavailability and atypical analytical data such as investigations for OOS Dissolution or related substances.

7:45 – 8:00 | Registration/Breakfast

8:00 – 8:10 | Welcome Catalent Connect Program Announcement

8:10 – 8:40 | Intro Presenter: Stephen Tindal Director of Science & Technology, Catalent
Perspectives in Partnership: How to leverage CDMO expert capabilities to give your clients the edge up.

8:45- 9:30 | Keynote Presenter: Alan F. Parr, Pharm.D., Ph.D. BioCeutics, LLC
The Cost of Failure: How to avoid the critical pitfalls in pharma consulting, and set your clients up for success

9:40-9:45 | Closing remarks / Adjourn